Core Viewpoint - Globalization remains the main theme for the medical device industry in 2025, with the company Yejuy Medical leading in the cardiovascular intervention field through a proactive global strategy, achieving an overseas revenue share of 88.4% [1][3]. Financial Performance - In the first half of 2025, the company reported total revenue of $83.55 million, a year-on-year increase of 5.9%, with product sales reaching 91,900 units, including 77,900 units of proprietary products, which saw an 8.6% increase [3][4]. - The net profit attributable to shareholders was $19.80 million, up 5.1%, while core operating profit reached $15.10 million, growing by 11.4% [3][4]. - The company announced a special dividend of 15 HKD per share, in addition to a previously declared dividend of 10 HKD per share, totaling 25 HKD per share for the year, reflecting management's confidence in long-term prospects [3][4]. Cash Flow Management - As of June 30, 2025, the company had cash and bank balances of $237 million, providing a solid financial safety net for R&D, product commercialization, global acquisitions, and capacity building [4][9]. Strategic Pillars for Growth - The company focuses on three strategic pillars: regional deepening, innovation and acquisitions, and capacity building [4][9]. - The Asia-Pacific region contributed $27.31 million in revenue, a 14% increase, with Indonesia showing significant growth [5][6]. - In Europe, the Middle East, and Africa, revenue grew by 17% to $22.43 million, driven by strong sales of proprietary balloon products [5][6]. Product Strategy - The company has over 250 authorized patents and has successfully obtained multiple product certifications, expanding its product portfolio [7][8]. - New product registrations and clinical trials are ongoing, with several products expected to launch globally in the coming years [7][8]. Production and Supply Chain - The company has established production bases in Shenzhen, the Netherlands, and Germany, with an annual capacity of approximately 2.1 million units, and a new facility in Hangzhou expected to add 2.4 million units by 2027 [9]. Market Outlook - Short-term catalysts include easing U.S. tariffs, the launch of high-end products in Japan, and the establishment of new direct sales teams in Europe [10]. - Long-term growth is supported by participation in volume-based procurement in China, the launch of self-developed products, and rising demand in emerging markets [10][11]. Market Valuation - The company's PE ratio as of August 15 was 13.174, indicating potential for upward growth compared to historical levels [11][13].